29
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Increased Production of lnterleukin-1β and lnterleukin-1 Receptor Antagonist by Peripheral Blood Mononuclear Cells in Undialyzed Chronic Renal Failure

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We investigated the cell content and production of IL-1β and IL-1 receptor antagonist (Ra) by unstimulated and lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC) obtained from 15 undialyzed patients with chronic renal failure (CRF; estimated GFR < 10ml/min), 15 patients on chronic hemodialysis (HD) and 15 healthy controls. These cytokines were measured by ELISA. The cell content of IL-1β in freshly obtained PBMC was not detectable in any group. In contrast, that of IL-1Ra in CRF (1,807 ± 370 pg/ml, p < 0.05) as well as in HD( 1,791 ± 151 pg/mlp < 0.001) was significantly higher than that of the controls (907 ± 156 pg/ml). In unstimulated cultured PBMC, spontaneous production of IL-1β in CRF (66 ± 13 pg/ml, p < 0.05) and in HD (81 ± 29 pg/ml, p < 0.05) was significantly higher than that of the controls (26 ± 3 pg/ml). In contrast, comparison of spontaneous production of IL-1Ra in the three groups was not significantly different. In LPS-stimulated PBMC, IL-1β production in CRF (10,896 ± 1,359 pg/ml, p < 0.01) and in HD(11,441 ± 1,400 pg/ml, p < 0.01) was significantly higher than that of the controls (6,117 ± 572 pg/ml). However, IL-1Ra production by LPS-stimulated PBMC in the three groups was not significantly different. Moreover, the spontaneous IL-lRa/IL-1β production ratio in CRF (140 ± 16, p < 0.01) and in HD (142 ± 19, p < 0.01) was significantly lower than that of the controls (294 ± 41). The present study demonstrates that cytokine production by PBMC in undialyzed CRF patients as well as in hemodialyzed patients is heightened and may induce impaired function of the immunological system before CRF patients are introduced to dialysis.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1997
          1997
          23 December 2008
          : 76
          : 1
          : 26-31
          Affiliations
          2nd Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
          Article
          190136 Nephron 1997;76:26–31
          10.1159/000190136
          9171296
          fb7792c9-54d0-4876-a108-acdae2d4cb8e
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 03 October 1996
          Page count
          Pages: 6
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          Interleukin 1&beta;,Peripheral blood mononuclear cells,Interleukin 1 receptor antagonist,Chronic renal failure,Hemodialysis

          Comments

          Comment on this article